日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

Chinese Alzheimer's drug to undergo global clinical trials

Source: Xinhua| 2020-01-04 18:58:21|Editor: zh
Video PlayerClose

BEIJING, Jan. 4 (Xinhua) -- An innovative Chinese Alzheimer's drug that hit the domestic market last week will go through clinical trials on 2,000 patients overseas in 2020.

The orally administered drug GV-971 will be tested in 200 clinical centers in North America, the European Union, Eastern Europe, Asia Pacific and other places, according to Green Valley Pharmaceutical Co., Ltd, one of the drug's co-developers.

The company said it plans to complete the global clinical trials in 2024 and submit the New Drug Application to the U.S. Food and Drug Administration and European Medicines Agency in 2025.

GV-971 was jointly developed by the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS), Ocean University of China and Green Valley, after a 22-year study.

The results of the mechanism of action study were published in the international journal Cell Research in September 2019, saying that the drug, extracted from brown algae, works by modifying gut bacteria to ultimately reduce brain inflammation in mice that were genetically engineered to have the disease.

It was approved to market last November by China's National Medical Products Administration, which said the GV-971 "can improve cognition in patients with mild to moderate Alzheimer's disease (AD)."

According to researchers, apart from animal experiments, more than 1,100 Chinese AD patients participated in clinical trials before the drug hit the market. In the last test, a total of 818 participants from 34 leading hospitals in China took 450 mg GV-971 orally twice a day for a treatment period of nine months, which proved safe and effective in improving cognition.

"Because of its effectiveness on Chinese patients, we expect this drug to benefit more people in the rest of the world," said Lyu Songtao, chairman of the Shanghai-based pharmaceutical company.

At least 50 million people worldwide have dementia and AD is the root cause behind 60 percent to 70 percent of the cases, according to the World Health Organization.

AD is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills and the ability to carry out simple tasks.

China currently has about 10 million AD patients and the number is expected to increase to 40 million by 2050, more than the population of Canada, according to China Association of Gerontology and Geriatrics.

The aging population and high medical costs are urgent tasks the country is facing. For Chinese AD patients, the average spending can reach 130,000 yuan (about 18,665 U.S. dollars) per year.

Lyu said the monthly cost of GV-971 is only about 3,580 yuan.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011100001386782961
主站蜘蛛池模板: 出差我被公高潮A片久久 | 少妇扒开双腿让我看个够 | 久久久久久逼 | 大地资源网视频观看免费高清 | 久久久久久亚洲精品视频 | 国产视频麻豆 | 国产一区三区四区 | 亚洲产国偷V产偷V自拍色戒 | a亚洲视频 | 亚洲人成在线观看无码 | 国产精品国产三级国产在线观什 | 日日爱影院 | 日本熟妇XXXⅩ50岁 | 一级黄色毛毛片 | 搡少妇在线视频少妇干活了 | 免费av在线网址 | 精品欧洲AV无码一区二区三区 | 国产精品18久久久不卡最新章节 | 日本三级吃奶头添泬播放 | 国产人妻一区二区三区四区五区六 | 日本xx高清| 一本久久a久久精品合男女 韩国成人免费视频 | 99精品人妻少妇一区二区 | 久久精品国产一区二区三区不卡 | 韩国av在线 | 国产八十老太另类 | 爱爱免费网 | 国产91丝袜香蕉在线播放 | 国产九区一区在线 | 93人妻人人揉人人澡人人 | 一级毛片影视 | 伊人网视频 | aⅴ在天堂线网在线观看 | 国精品人妻无码一区二区三区软件 | 成年人a | 亚洲卡通欧美制服中文 | 666av视频在线观看 | 国产成人亚洲精品无码综合原创 | 亚洲国产精品欧美一二99 | 91高跟黑色丝袜呻吟在线观看 | 亚洲国产成人A精品不卡在线 |